Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis

被引：8
|
作者：
Christopher, Karen L. [1 ]
Elner, Victor M. [1 ]
Demirci, Hakan [1 ]
机构：
[1] Univ Michigan, Dept Ophthalmol & Visual Sci, WK Kellogg Eye Ctr, 1000 Wall St, Ann Arbor, MI 48109 USA
来源：
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY | 2017年 / 33卷 / 03期
关键词：
B-CELL LYMPHOMA; RITUXIMAB;
D O I：
10.1097/IOP.0000000000000774
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
The authors describe a 39-year-old woman treated with fingolimod for relapsing-remitting multiple sclerosis for 2 years who then developed a bilateral conjunctival mucosa-associated lymphoid tissue lymphoma. Fingolimod treatment for multiple sclerosis has been associated with lymphoma in 3 previously reported cases. This is the first case of ocular adnexal lymphoma presumed to be due to fingolimod. Given that ophthalmologists regularly monitor many patients on fingolimod for fingolimod-associated macular edema and ophthalmic manifestations of multiple sclerosis, the authors hope to alert physicians of the possibility of ocular adnexal lymphoma in these patients.
引用
收藏
页码：E73 / E75
页数：3
相关论文
共 50 条
  • [1] The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
    Boz, Cavit
    Ozakbas, Serkan
    Terzi, Murat
    Karabudak, Rana
    Sevim, Serhan
    Turkoglu, Recai
    Soysal, Aysun
    Balci, Belgin Petek
    Efendi, Husnu
    Turan, Omer Faruk
    Yuceyar, Nur
    Yetkin, Mehmet Fatih
    Karahan, Serap Zengin
    Demirkiran, Meltem
    Guler, Sibel
    Agan, Kadriye
    Kiylioglu, Nefati
    Baba, Cavid
    Tuncer, Asli
    Koseoglu, Mesrure
    NEUROLOGICAL SCIENCES, 2023, 44 (06) : 2121 - 2129
  • [2] Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis
    Menge, Til
    Dubey, Divyanshu
    Warnke, Clemens
    Hartung, Hans-Peter
    Stuve, Olaf
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (10) : 1131 - 1139
  • [3] Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe
    Alcala, Carmen
    Gascon, F.
    Perez-Miralles, Francisco
    Dominguez, J. A.
    Gil-Perotin, S.
    Casanova, B.
    JOURNAL OF NEUROLOGY, 2019, 266 (03) : 726 - 734
  • [4] Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Cohort Study
    Hernandez-Preciado, Martha Rocio
    Marquez-Pedroza, Jazmin
    Sanchez-Rosales, Nayeli Alejandra
    Garcia-Rivera, Jose de Jesus
    Kobayashi-Gutierrez, Antonio
    Torres-Mendoza, Blanca Miriam
    Chavarria-Avila, Efrain
    Montano-Serrano, Raul Alejandro
    Cortes-Enriquez, Fernando
    Mireles-Ramirez, Mario Alberto
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (13)
  • [5] Discontinuation and dose reduction of rituximab in relapsing-remitting multiple sclerosis
    Boremalm, Malin
    Sundstrom, Peter
    Salzer, Jonatan
    JOURNAL OF NEUROLOGY, 2021, 268 (06) : 2161 - 2168
  • [6] The Effect of Rituximab on the Cognitive Function of Patients with Relapsing-Remitting Multiple Sclerosis
    Najafi, Masood
    Farahmand, Ghasem
    Balali, Pargol
    Behkar, Atefeh
    Shahbazi, Mojtaba
    Moradian, Negar
    Pouyanmanouchehri, Sara
    Harirchian, Mohammad Hossein
    Ranji, Sara
    CLINICAL THERAPEUTICS, 2024, 46 (10) : e1 - e5
  • [7] Immunological Subsets Characterization in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis
    D'Amico, Emanuele
    Zanghi, Aurora
    Parrinello, Nunziatina Laura
    Romano, Alessandra
    Palumbo, Giuseppe Alberto
    Chisari, Clara Grazia
    Toscano, Simona
    Raimondo, Francesco Di
    Zappia, Mario
    Patti, Francesco
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [8] The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective
    Alroughani, Raed
    Van Wijmeersch, Bart
    Al Khaboori, Jabber
    Alsharoqi, Isa Ahmed
    Ahmed, Samar F.
    Hassan, Ali
    Inshasi, Jihad
    Krieger, Derk W.
    Shakra, Mustafa
    Shatila, Ahmed Osman
    Szolics, Miklos
    Khallaf, Mohamed
    Ezzat, Aly
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2020, 13
  • [9] Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis The MIRROR study
    Bar-Or, Amit
    Grove, Richard A.
    Austin, Daren J.
    Tolson, Jerry M.
    VanMeter, Susan A.
    Lewis, Eric W.
    Derosier, Frederick J.
    Lopez, Monica C.
    Kavanagh, Sarah T.
    Miller, Aaron E.
    Sorensen, Per S.
    NEUROLOGY, 2018, 90 (20) : E1805 - E1814
  • [10] Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal
    Rollot, Fabien
    Couturier, Justine
    Casey, Romain
    Wiertlewski, Sandrine
    Debouverie, Marc
    Pelletier, Jean
    De Seze, Jerome
    Labauge, Pierre
    Ruet, Aurelie
    Thouvenot, Eric
    Ciron, Jonathan
    Berger, Eric
    Gout, Olivier
    Clavelou, Pierre
    Stankoff, Bruno
    Casez, Olivier
    Bourre, Bertrand
    Zephir, Helene
    Moreau, Thibault
    Lebrun-Frenay, Christine
    Maillart, Elisabeth
    Edan, Gilles
    Neau, Jean-Philippe
    Montcuquet, Alexis
    Cabre, Philippe
    Camdessanche, Jean-Philippe
    Defer, Gilles
    Ben Nasr, Haifa
    Maurousset, Aude
    Hankiewicz, Karolina
    Pottier, Corinne
    Leray, Emmanuelle
    Vukusic, Sandra
    Laplaud, David-Axel
    NEUROTHERAPEUTICS, 2022, 19 (02) : 476 - 490
12345